ArticleCancer cell international2025
GADD45GIP1 promotes osteosarcoma progression by modulating RPL35 ubiquitination and alleviating endoplasmic reticulum stress via the PERK/eIF2α pathway.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unresolved questions on the GADD45GIP1-RPL35 axis in osteosarcoma: mechanistic links to ER stress and therapeutic targeting.Cancer cell international · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteosarcoma, a common and aggressive bone tumor found in adolescents and children, is associated with a poor prognosis. The investigation of new molecular mechanisms is deemed vital for the development of innovative treatments. Transcriptomic survival analysis and single-cell RNA sequencing have identified seven highly expressed genes, including GADD45G interacting protein 1 (GADD45GIP1), that are linked to poor prognosis in patients with osteosarcoma. Tissue arrays, comprising 41 normal and 67 tumor cases, have further confirmed the high expression of GADD45GIP1 in osteosarcoma. Functional tests have demonstrated that the silencing of GADD45GIP1 significantly reduces the migration and proliferation of osteosarcoma cells in vitro and in vivo, while its overexpression has the opposite effect. Mechanistic studies have revealed 263 proteins that potentially interact with GADD45GIP1, identified through immunoprecipitation (IP) and liquid chromatography-tandem mass spectrometry (LC-MS/MS), with RPL35 ranking second among them. Cellular interference with RPL35 has been shown to activate the PERK-eIF2α pathway, increase endoplasmic reticulum (ER) stress, and affect the biological behavior of tumor cells. Additionally, the knockdown of GADD45GIP1 has led to a decrease in RPL35 protein stability and elevated polyubiquitination. Notably, the overexpression of RPL35 has counteracted the decrease in cell vitality induced by GADD45GIP1 knockdown. Thus, the high expression of GADD45GIP1 in osteosarcoma has been shown to inhibit the ubiquitin-mediated degradation of RPL35 and induce ER stress through the activation of the PERK-eIF2α pathway, thereby promoting the progression of osteosarcoma. This indicates that GADD45GIP1 serves as a key driver in the development of osteosarcoma and is a potential target for the prevention and therapy of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.